AL102 PDUFA date

The PDUFA goal date for AL102 (varegacestat) is 28 Apr 2027, as disclosed by Immunome, Inc. (IMNM).

PDUFA date
28 Apr 2027

Drug identity checked against registry records

Also recorded as varegacestat

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of AL102 in Patients With Progressing Desmoid TumorsNCT04871282IMNMPhase 2, Phase 3Active not recruiting2025-12-03Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-04-28DayAL102Immunome, Inc. · IMNMCompany-disclosed PDUFA goal dateAnnounced review targetNot specifiedOpen original source
Read source excerpt

an NDA for varegacestat to the FDA, which was assigned a PDUFA target action date of April 28, 2027

First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026

2027-04-28DayAL102Immunome, Inc. · IMNMCompany-disclosed PDUFA goal dateAnnounced review targetNot specifiedOpen original source
Read source excerpt

Varegacestat PDUFA target action date of April 28, 2027

First seen: 11 Nov 2026 · Evidence last checked: 11 Nov 2026